Keeping Track: Good News/Bad News For Pfizer; Filings For Brexanolone, Risankizumab
The latest US drug development news and highlights from our Performance Tracker.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Sun says that it is "excited" with Ilumya’ s initial launch uptake in the crowded US psoriasis segment, but is pushing ahead with "speedy execution" of plans for the product before the potential arrival of new rivals such as AbbVie’s same-class therapy risankizumab.
The latest drug development news and highlights from our FDA Performance Tracker.